Ulipristal acetate for unscheduled bleeding in etonogestrel implant users: A randomized controlled trial
Obstetrics and Gynecology Sep 28, 2018
Zigler RE, et al. - Researchers investigated the efficacy of ulipristal acetate vs placebo in reducing the number of bleeding days in etonogestrel implant users in a 30-day period. As per outcomes, etonogestrel contraceptive implant users found ulipristal acetate to be well-tolerated with a reduced number of bleeding days.
Methods
- Researchers undertook a single-center, randomized, double-blind, placebo-controlled trial.
- Women aged 18–45 years with an etonogestrel implant in place for greater than 90 days and less than 3 years who reported greater than one bleeding episode in a 24-day period were eligible for participation.
- They provided 15 mg ulipristal acetate to enrolled participants compared with an identical-appearing placebo daily for 7 days.
- Using automated text messaging, participants completed daily bleeding diaries to evaluate whether ulipristal acetate reduces the number of bleeding days as compared with placebo.
- Participant satisfaction with bleeding and the effect of ulipristal acetate on ovulation status were assessed as the secondary outcomes.
- They planned a sample size of 52 per group (n=104), calculated with an effect size of a 30% reduction in bleeding days, SD of 10 days, and dropout of 15%.
- They evaluated the effect of ulipristal acetate on ovulatory potential in a subset with weekly serum progesterone.
Results
- Researchers allocated 65 women to receive 15 mg ulipristal acetate (n=32) or placebo (n=33) daily for 7 days from May 2017 to January 2018.
- The groups were similar regarding demographic characteristics.
- Findings revealed 5 fewer days of bleeding over a 30-day reference period after treatment among women receiving ulipristal acetate (P=.002).
- Women in the ulipristal acetate group vs the placebo group were more satisfied with their bleeding profile at the end of the 30-day follow-up period (87.5% vs 60%, respectively; P < .001).
- In a subset of each group, serum progesterone levels were nonovulatory (placebo group range: less than 0.2–1.3 ng/mL; ulipristal acetate group range: less than 0.2–4.4 ng/mL).
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries